Issste, at the forefront of pulmonary arterial hypertension treatments / @drpedrozenteno @ISSSTE_mx >>>

#ISSSTE.- The new Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (Issste) is at the forefront by having all the therapeutic alternatives available and approved in Mexico for the treatment of the different groups and types of pulmonary arterial hypertension (PAH); it is difficult to diagnose and each cause merits differentiated management.

The General Director, Pedro Zenteno Santaella, emphasized that the Institute is a pioneer in the incorporation of specific advanced therapies for some types of primary PAH, which has made it possible in the last 15 years to increase patient survival, which used to be 2.4 years and is now 10 years, under quality conditions.

In this regard, Guadalupe Espitia Hernández, a pulmonologist at Issste’s «1° de Octubre» Regional Hospital, with a high specialty in interstitial lung disease (ILD) and PAH, said that the target therapies available to the institution are specific drugs that act on different mechanisms of some variants.

«Currently, we attend patients who have gone through various treatment strategies and are completing around 12 or 13 years of survival under close medical surveillance by highly qualified multidisciplinary teams.»

#MéxicoNewsTv – México News tv